Development and characterization of phospholipid-stabilized submicron aqueous dispersions of coenzyme Q10 presenting continuous vibrating-mesh nebulization performance

Journal of Liposome Research

Volumn 23, Issue 4, 2013, Pages 276-290

  Carvalho, Thiago C ^a   McCook, John P ^b   Narain, Niven R ^c   McConville, Jason T ^d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Berg Pharma   (United States)

^c Berg Pharma   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Anticancer agents; Formulation development; Inhalation delivery; Nebulizers; Rheology; Suspensions

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; UBIDECARENONE;

ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; FLOW KINETICS; HYDRODYNAMICS; MELTING POINT; METERED DOSE INHALER; MICROFLUIDICS; NEBULIZATION; NEBULIZER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCALE UP;

MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHOSPHOLIPIDS; SURFACE TENSION; UBIQUINONE; VIBRATION; WATER; X-RAY DIFFRACTION;

EID: 84885454757     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.796976     Document Type: Article

References (50)

1. Abdelrahim ME, Plant P, Chrystyn H. (2010). In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol 62:966-72.
2. Alfridsson M, Ninham B, Wall S. (2000). Role of Co-Ion specificity and dissolved atmospheric gas in colloid interaction. Langmuir 16: 10087-91. (Pubitemid 32086252)
3. Barnes HA, Hutton JF, Walters K. (1989). Rheology of suspensions. In: Walters K, ed. An introduction to rheology. Amsterdam, The Netherlands: Elsevier, 115-37.
4. Bhagavan HN, Chopra RK. (2006). Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Rad Res 40:445-53.
5. Bhagavan HN, Chopra RK. (2007). Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 7: S78-88. (Pubitemid 46712234)
6. Bittar EE, ed. (2002). Alveolar surfactant. In: Pulmonary biology in health and disease. New York, NY, USA: Springer, 44-63.
7. Boe J, Dennis JH, O'Driscoll BR. (2001). European Respiratory Society Guidelines on the use of nebulizers. Eur Respirat J 18:228-42. (Pubitemid 32717452)
8. Brea-Calvo G, Rodríguez-Hernández A ́, Fernández-Ayala DJM, et al. (2006). Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. Free Rad Biol Med 40:1293-302.
9. Carvalho T, Horng M, McConville J. (2012). Application of a pull on a disk method to measure surface tension of liquids. AAPS PharmSciTech 13:305-12.
10. Carvalho TC, Peters JI, Williams III RO. (2011). Influence of particle size on regional lung deposition-What evidence is there? Int J Pharma 406:1-10.
11. Dhanasekaran M, Ren J. (2005). The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovascular Res 2:447-59. (Pubitemid 41789609)
12. Elhissi A, Gill H, Ahmed W, Taylor K. (2011). Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. J Liposome Res 21:173-80.
13. Elhissi AMA, Faizi M, Naji WF, et al. (2007). Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharma 334:62-70. (Pubitemid 46400313)
14. Elhissi AMA, Karnam KK, Danesh-Azari MR, et al. (2006). Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J Pharm Pharmacol 58:887-94. (Pubitemid 43967104)
15. Elhissi AMA, Taylor KMG. (2005). Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J Drug Deliv Sci Technol 15:261-5. (Pubitemid 41223726)
16. Finer NN, Merritt TA, Bernstein G, et al. (2010). An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulmonary Drug Deliv 23:303-9.
17. Folkers K, Brown R, Judy WV, Morita M. (1993a). Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192:241-5. (Pubitemid 23205292)
18. Folkers K, Morita M, McRee J. (1993b). The activities of coenzyme- Q(10) and vitamin-B(6) for immune-responses. Biochem Biophys Res Commun 193:88-92. (Pubitemid 23199916)
19. Ghazanfari T, Elhissi AMA, Ding Z, Taylor KMG. (2007). The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharmaceut 339:103-11. (Pubitemid 46977598)
20. Ghodrat M. (2006). Lung surfactants. Am J Health-System Pharm 63: 1504-21.
21. Gurkan AS, Bozdag-Dundar O. (2005). Coenzyme Q10. J Fac Pharm Ankara 34:129-54.
22. Hertz N, Lister RE. (2009). Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int Med Res 37:1961-71.
23. Hintze J. (2001). NCSS and PASS, released January 29th, 2004 edn. Kaysville, UT, USA: Number Cruncher Statistical Systems.
24. Jin YL, Chen JY, Xu L,Wang PN. (2006). Refractive index measurement for biomaterial samples by total internal reflection. Phys Med Biol 51: N371-9. (Pubitemid 44540118)
25. Kawaguchi E, Shimokawa K, Ishii F. (2008). Physicochemical properties of structured phosphatidylcholine in drug carrier lipid emulsions for drug delivery systems. Colloids Surf B-Biointerfaces 62:130-5.
26. Lasch J, Weissig V, Brandl M. (2003). Preparation of liposomes. In: Torchilin VP, Weissig V, eds. Liposomes: a practical approach. 2nd edn. Oxford, UK: Oxford University Press, 3-29.
27. Marple VA, Olson BA, Santhanakrishnan K, et al. (2004). Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/ min. J Aerosol Med-Depos Clear Eff Lung 17:335-43. (Pubitemid 40116950)
28. McConville JT, Overhoff KA, Sinswat P, et al. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharmaceut Res 23:901-11. (Pubitemid 43781398)
29. Mitchell JP, Nagel MW, Nichols S, Nerbrink O. (2006). Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aerosol Med-Depos Clear Eff Lung 19: 409-33. (Pubitemid 46067762)
30. Narain NR, Li J, Russell KJ, et al. (2004a). Coenzyme Q10 inhibits the proliferation of oncogenic cells while stabilizing growth in primary cells in vitro. J Investigative Dermatol 122:167.
31. Narain NR, Li J, Woan KV, et al. (2004b). Coenzyme Q10 induces apoptosis in human melanoma cells. J Investigative Dermatol 122: 958.
32. Ondarroa M, Sharma SK, Quinn PJ. (1986). Solvation properties of ubiquinone-10 in solvents of different polarity. Biosci Rep 6:783-96. (Pubitemid 17222884)
33. Packhaeuser CB, Lahnstein K, Sitterberg J, et al. (2009). Stabilization of aerosolizable nano-carriers by freeze-drying. Pharmaceutical Res 26: 129-38.
34. Pilcer G, Amighi K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharmaceutics 392:1-19.
35. Pinto L, Sloan A, Persaud I, Narain NR. (2009). Normalization of BCL-2 family members in breast cancer by coenzyme Q10. Ethnicity Dis 19: S17-18.
36. Randall C. (1995). Particle size distribution. In: Brittain HG, ed. Physical characterization of pharmaceutical solids. New York, NY: M. Dekker, 157-86.
37. Rottier BL, van Erp CJP, Sluyter TS, et al. (2009). Changes in performance of the Parie Flow rapid and Pari LC PlusTM during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 22:263-9.
38. Rusciani L, Proietti I, Rusciani A, et al. (2006). Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 54:234-41. (Pubitemid 43144392)
39. Shekunov BY, Chattopadhyay P, Tong HHY, Chow AHL. (2007). Particle size analysis in pharmaceutics: principles, methods and applications. Pharmaceut Res 24:203-27. (Pubitemid 46072181)
40. Siekmann B, Westesen K. (1995). Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharmaceut Res 12:201-8.
41. Smart J, Berg E, Nerbrink O, et al. (2002). TouchSprayTM technology: comparison of the droplet size measured with cascade impaction and laser diffraction. In: Dalby RN, Byron PR, Peart J, Farr SJ, eds. Respiratory drug delivery VIII, Tucson, AZ, USA. Richmond, VA, USA: Virginia Commonwealth University, 525-8.
42. Taeusch HW, Lu K, Ramierez-Schrempp D. (2002). Improving pulmonary surfactants. Acta Pharmacol Sinica 23:11-15. (Pubitemid 35477165)
43. Tam JM, McConville JT, Williams RO, Johnston KP. (2008). Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharmaceut Sci 97:4915-33.
44. USP. (2011).516014Products for nebulization-characterization tests. In: The United States Pharmacopeial Convention, ed. USP 34-NF 29. Baltimore: United Book Press, Inc.
45. Vaughn JM, McConville JT, Burgess D, et al. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharmaceut Biopharmaceut 63:95-102. (Pubitemid 43776206)
46. Washington C. (1996). Stability of lipid emulsions for drug delivery. Advanced Drug Deliv Rev 20:131-45. (Pubitemid 26284153)
47. Watts AB, McConville JT, Williams RO. (2008). Current therapies and technological advances in aqueous aerosol drug delivery. Drug Develop Industrial Pharmacy 34:913-22.
48. Wu YZ, Wang T. (2003a). Phospholipid class and FA compositions of modified soybeans processed with two extraction methods. J Am Oil Chemists Soc 80:127-32.
49. Wu YZ, Wang T. (2003b). Soybean lecithin fractionation and functionality. J Am Oil Chemists Soc 80:319-26.
50. Zhang G, David A, Wiedmann TS. (2007). Performance of the vibrating membrane aerosol generation device: aeroneb micropump nebulizerTM. J Aerosol Med-Depos Clear Eff Lung 20:408-16.